Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 1
1991 1
1992 1
1993 2
1994 1
1995 2
1996 2
1997 7
1998 4
1999 8
2000 1
2001 2
2002 1
2003 4
2004 2
2005 2
2006 10
2007 6
2008 3
2009 9
2010 5
2011 7
2012 4
2013 12
2014 13
2015 18
2016 13
2017 12
2018 9
2019 6
2020 13
2021 11
2022 13
2023 8
2024 11
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208 results

Results by year

Filters applied: . Clear all
Page 1
Bromfenac Ophthalmic Solution 0.07%: A Review of Its Use After Cataract Surgery.
Hoy SM. Hoy SM. Clin Drug Investig. 2015 Aug;35(8):525-9. doi: 10.1007/s40261-015-0309-3. Clin Drug Investig. 2015. PMID: 26177719 Review.
The nonsteroidal anti-inflammatory drug bromfenac has recently been reformulated with a lower pH to facilitate a reduction in the concentration of bromfenac (to 0.07%) while ensuring an ocular bioavailability similar to that of the 0.09% formulation. Bromfenac …
The nonsteroidal anti-inflammatory drug bromfenac has recently been reformulated with a lower pH to facilitate a reduction in the con …
Topical bromfenac in VEGF-driven maculopathies: topical review and meta-analysis.
Kulikov AN, Vasiliev AS, Kalinicheva YA, Maltsev DS. Kulikov AN, et al. BMC Ophthalmol. 2024 Aug 23;24(1):369. doi: 10.1186/s12886-024-03650-z. BMC Ophthalmol. 2024. PMID: 39180057 Free PMC article. Review.
In this review, we focused on the advantages of topical bromfenac as an adjunct to intravitreal anti-VEGF therapy in VEGF-driven maculopathies. ...At the same time, eyes receiving bromfenac as an adjunct to anti-VEGF therapy demonstrated non-inferior outcomes in cen …
In this review, we focused on the advantages of topical bromfenac as an adjunct to intravitreal anti-VEGF therapy in VEGF-driven macu …
Effect of Bromfenac on Reducing Neuroinflammation in an Ischemia-Reperfusion Glaucoma Model.
Oh SE, Kim JH, Park CK, Park HL. Oh SE, et al. Cells. 2024 Jun 17;13(12):1046. doi: 10.3390/cells13121046. Cells. 2024. PMID: 38920673 Free PMC article.
Bromfenac's impact on microglia and astrocytes under pressure was assessed via Western blotting and an enzyme-linked immunosorbent assay. ...In summary, Bromfenac proved effective in diminishing neuroinflammation and resulted in enhanced RGC survival....
Bromfenac's impact on microglia and astrocytes under pressure was assessed via Western blotting and an enzyme-linked immunosorbent as …
Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent.
Jones J, Francis P. Jones J, et al. Expert Opin Pharmacother. 2009 Oct;10(14):2379-85. doi: 10.1517/14656560903188425. Expert Opin Pharmacother. 2009. PMID: 19735215 Review.
Adverse events associated with use have been minimal in large studies, although there are reports of corneal compromise with bromfenac use in cases of preexisting corneal disease. The comfort and reduced frequency of use offered by bromfenac would be expected to imp …
Adverse events associated with use have been minimal in large studies, although there are reports of corneal compromise with bromfenac …
Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets.
Dang DH, Riaz KM, Karamichos D. Dang DH, et al. Drugs. 2022 Feb;82(2):145-167. doi: 10.1007/s40265-021-01660-5. Epub 2022 Jan 13. Drugs. 2022. PMID: 35025078 Free PMC article. Review.
Steroidal anti-inflammatory agents are frequently used as part of the therapeutic regimen. A variety of commonly used agents, including prednisolone acetate, loteprednol, difluprednate, dexamethasone, fluorometholone, and methylprednisolone are discussed. ...Non-steroidal …
Steroidal anti-inflammatory agents are frequently used as part of the therapeutic regimen. A variety of commonly used agents, includi …
Efficacy and safety of bromfenac 0.075% formulated in DuraSite for pain and inflammation in cataract surgery.
Wentz SM, Price F, Harris A, Siesky B, Ciulla T. Wentz SM, et al. Expert Opin Pharmacother. 2019 Oct;20(14):1703-1709. doi: 10.1080/14656566.2019.1645834. Epub 2019 Jul 25. Expert Opin Pharmacother. 2019. PMID: 31343372 Review.
Introduction: Bromfenac is a topical ophthalmic non-steroidal anti-inflammatory drug (NSAID) used to reduce pain and treat post-operative inflammation after cataract surgery. Bromfenac 0.075% in the DuraSite vehicle is a newly-approved formulation which has been sho …
Introduction: Bromfenac is a topical ophthalmic non-steroidal anti-inflammatory drug (NSAID) used to reduce pain and treat post-opera …
Clinical pharmacokinetics and pharmacodynamics of bromfenac.
Skjodt NM, Davies NM. Skjodt NM, et al. Clin Pharmacokinet. 1999 Jun;36(6):399-408. doi: 10.2165/00003088-199936060-00002. Clin Pharmacokinet. 1999. PMID: 10427465 Review.
Bromfenac is a nonsteroidal anti-inflammatory drug whose peak plasma concentration is reached 0.5 hours after oral administration. ...Renal disease, hepatic disease and aging alter the disposition kinetics of bromfenac, and dosage adjustment may be advisable. Bro …
Bromfenac is a nonsteroidal anti-inflammatory drug whose peak plasma concentration is reached 0.5 hours after oral administration. .. …
Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema.
Gabr AF, Kamel MF, Elbarawy AA. Gabr AF, et al. Int Ophthalmol. 2023 Sep;43(9):3219-3226. doi: 10.1007/s10792-023-02722-1. Epub 2023 Apr 21. Int Ophthalmol. 2023. PMID: 37083870 Free PMC article. Clinical Trial.
The efficacy of topical bromfenac was evaluated by comparing both groups through follow-up period as regards to visual acuity, central and average thickness and the need for re-injection. ...No side effects was encountered with the use of topical bromfenac. CONCLUSI …
The efficacy of topical bromfenac was evaluated by comparing both groups through follow-up period as regards to visual acuity, centra …
Drug-induced hepatotoxicity.
Lee WM. Lee WM. N Engl J Med. 2003 Jul 31;349(5):474-85. doi: 10.1056/NEJMra021844. N Engl J Med. 2003. PMID: 12890847 Review. No abstract available.
A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience.
Goldkind L, Laine L. Goldkind L, et al. Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):213-20. doi: 10.1002/pds.1207. Pharmacoepidemiol Drug Saf. 2006. PMID: 16456879
There were very limited published data on benoxaprofen and none on ibufenac or bromfenac. The publicly accessible archives of the FDA provided information on bromfenac. ...Following approval, rates of acute liver failure for bromfenac were estimated to be in …
There were very limited published data on benoxaprofen and none on ibufenac or bromfenac. The publicly accessible archives of the FDA …
208 results